ALTO NEUROSC. DL-,0001. Aktie

Alto Neuroscience showcased its clinical pipeline at the H.C. Wainwright conference, with ALTO-207 for treatment-resistant depression as the centerpiece. ALTO-207 is expected to enter Phase 3 in early 2027; top-line data from the ongoing Phase 2b study are anticipated in the second half of 2027. Two other Phase 2b programs, ALTO-300 (major depression) and ALTO-100 (bipolar depression), will also deliver important data in 2027 and could advance to Phase 3. Management emphasized a biomarker-driven precision strategy for better patient selection, improved study quality through stricter screening, a cash position described as “excellent,” and a partnership review for ALTO-101. » More on de.investing.com

Alto Neuroscience shares rose to a record high of 35.42 USD, lifting the market capitalization to about 1.38 billion USD. Over the past 12 months the stock is up roughly 794% and year-to-date about 92.6%. InvestingPro analysis notes point to a possible overvaluation relative to fair value and an overbought RSI. Alto announced an equity placement of 100 million USD at 26.48 USD per share, published a Nature Medicine study supporting the mechanism of action of pramipexole, received a 55 USD price target from H.C. Wainwright, and appointed Dr. Andrew Miller to its board. » More on de.investing.com

Alto Neuroscience’s stock climbed to an all-time high of $32.74 and is currently trading around $32.94, implying a market capitalization of about $1.25 billion. InvestingPro rates the stock as relatively overvalued after it rose 906.09% last year. Alto plans a share placement at $26.48 per share with expected gross proceeds of around $100 million and anticipates closing the transaction soon. H.C. Wainwright reaffirmed a buy recommendation with a $50.00 price target; the company also reported new positive study results supporting a mechanism of action, the appointment of Dr. Andrew Miller to the board, and the accelerated start of the Phase 2b study of ALTO-207. » More on de.investing.com

Alto Neuroscience shares rose to an all‑time high of $29.34, bringing market capitalization to about $1.09 billion after a year-to-date gain of more than 840%. The company announced an equity offering of $100 million at $26.48 per share and expects the deal to close soon. A study in Nature Medicine showed that pramipexole significantly reduced anhedonia in patients with mood disorders; a Phase 2b trial of ALTO‑207 also started earlier than planned. H.C. Wainwright reiterated a buy rating with a $50.00 price target, and Dr. Andrew Miller was appointed to the board. » More on de.investing.com

Alto Neuroscience announced a committed direct offering of 3,776,436 common shares at $26.48 per share and expects gross proceeds of about $100 million. The offering price is near the 52-week high after the stock rose 918% last year. The company plans to use the proceeds to accelerate clinical development of ALTO-207, including a planned additional Phase 3 study in treatment‑resistant depression, and for general corporate purposes; EcoR1 Capital led the financing. Closing of the offering is expected on Tuesday, subject to customary conditions. » More on de.investing.com